文献速递骨显像与常规 SPECT肿瘤 PET/CT

椎体骨坏死在18F-FDG PET上模仿恶性病变

Vertebral Body Osteonecrosis Mimicking Malignant Disease on 18F-FDG PET.
PubMed 文献 · Clin Nucl Med · 2022-10-21

本文报告一名24岁非霍奇金淋巴瘤男性化疗后出现椎体骨坏死,中期PET示部分代谢缓解,治疗后PET示T4、T5椎体摄取增高被误判为复发性椎体病变,9天后复查PET未经治疗胸椎摄取消退,随访PET示胸椎光子稀疏伴CT硬化,MRI表现符合骨坏死。

要点

  • 化疗后椎体骨坏死可在18F-FDG PET上表现为短暂性摄取增高,模仿复发性椎体病变。
  • 未经间隔治疗,9天后复查PET胸椎摄取自行消退。
  • 随访PET示胸椎光子稀疏伴CT硬化,MRI表现符合骨坏死。

核心结论

  • 化疗后椎体骨坏死可在18F-FDG PET上表现为短暂性摄取增高,最初被误判为复发性结外病变。

研究设计与样本

  • 本文报告一例24岁非霍奇金淋巴瘤男性化疗后出现椎体骨坏死的病例。

主要发现

  • 中期再分期PET示部分代谢缓解,治疗后PET示T4和T5椎体摄取增高,被解读为复发性椎体病变。
  • 9天后复查PET未经间隔治疗示胸椎摄取消退。
  • 随访PET示胸椎光子稀疏伴CT硬化,提示骨坏死,MRI表现符合该诊断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report a case of vertebral osteonecrosis after chemotherapy in a 24-year-old man with non-Hodgkin lymphoma, with transient avidity on 18F-FDG PET initially misinterpreted as recurrent extranodal disease. The patient demonstrated a partial metabolic response on midtreatment restaging PET; however, posttreatment PET showed an increase in uptake in T4 and T5 vertebrae, interpreted as recurrent vertebral disease. Repeat PET performed 9 days later showed resolution of thoracic vertebral uptake without interval treatment. On follow-up PET study, thoracic vertebrae demonstrated photopenia with sclerosis on CT, concerning for osteonecrosis. MRI features were concordant with this diagnosis.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Chaudhary K, Ngai S. Vertebral Body Osteonecrosis Mimicking Malignant Disease on 18F-FDG PET. Clin Nucl Med. 2022. PMID: 36723894. doi:10.1097/RLU.0000000000004453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。